Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2017 08:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results

– Phase 3 Enrollment Progress Supports NDA Submissions for LDL-C Lowering Indications for Bempedoic Acid / Ezetimibe Combination Pill and Bempedoic Acid by the First Quarter 2019 –– Conference Call...